TME Pharma Raises €500,000 via New Bond Issuance with Shareholder Warrants

TME Pharma to Fund Via New Bond and Claim a New Notice of Shareholding

Announcement

TME pharma NV, a known clinical-stage biotechnology company pioneering in the development of therapies for eye disease and cancer, has stepped into fundraising of €500,000 to stabilize its financial capacity, following the fundraising of €1.7 M as of May 2025. The enhanced financial capacity will power up TME Pharmas position further in discussions with the financial smart partners. This will help the company to get ready for the future investments negotiated by TME Pharma, which the organization will continue to keep shareholders updated.

TMEs Plans

TME Pharma is planning to accelerate its financial capacity via the issuance of regular debt through private contractual agreements with European investors, agreed in exchange for €500,000 in cash. On 28th August 2025, the bonds will be issued at 85.4% of nominal value, also repaid by the company in cash on maturity at a nominal value of 93.5%. 28th August 2025 is the closing date for receipt of cash on the same date when the warrants and bonds will be issued. According to the bond issuance, the 6,387,055 private and non-tradable warrants will be filed with the bonds that will give holders access to subscribe for one common share in TME Pharma. With each warrant subjected to adjustment of a certain number of shares as described below.

The strike price of €0.11 per warrant is a 2,12% premium to the volume weighted average share price (VWAP) for the 10 from preceding the primary announcement of this bond issuance, officially declared on 25th August 2025. In the last few months, TME Pharma has executed measures to suddenly reduce costs effective on 1st July 2025, in securing the companys crucial assets. This transaction focuses on increasing the financial area, also applying certain limitations to the near-term dilution potential for the existing shareholders by initiating debt repayable in cash.

Further, the warrants issued during the transaction have submerged potential; their strike price is more than the current share price. If all warrants are strikable, the warrant strike will add €702,576 to the company in cash. The proceedings with this financing will contribute to TME Pharmas research and development activities. The company has currently announced its treasury investment strategy and the findings for the capable partnerships and acquisitions in successful businesses. With the analysis of TME Pharmas tax carry-forward losses, the company will consistently work on generating a fundamentally successful corporate structure. As a result, the revenue from non-core activities will contribute to and strengthen the development of its patented drug candidates.